Skip to main content
Kent Academic Repository

Off-licence use of clozapine: lessons from an inner-city NHS trust – comparison with other NHS Trusts

Whiskey, Eromona, Oloyede, Ebenezer, Dzahini, Olubanke, Aziri, Helena, Cheung, Henry, Leech, Michelle, Helthuis, Marinka, Taylor, David, Shergill, Sukhi (2026) Off-licence use of clozapine: lessons from an inner-city NHS trust – comparison with other NHS Trusts. Schizophrenia Research, 297 . pp. 194-201. ISSN 0920-9964. E-ISSN 1573-2509. (doi:10.1016/j.schres.2026.08.010) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:117735)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided.
Contact us about this publication
Official URL:
https://doi.org/10.1016/j.schres.2026.08.010

Abstract

Introduction

Clozapine remains the only licensed antipsychotic for individuals with treatment-resistant schizophrenia. Despite its proven effectiveness, clozapine continues to be significantly underutilised. This underuse is attributed to multiple barriers, including the requirement for lifelong haematological monitoring, adverse effects often leading to discontinuation and complex regulatory constraints. Off-licence prescribing offers a pragmatic approach to mitigating some of these challenges and improving access. To date, it remains unclear how this approach is used in clinical practice and how its use may vary across hospitals.

Method

We analysed the Zaponex Treatment Access System (ZTAS) registries of four large NHS hospitals in November 2025. These trusts were chosen for comparison because of their ethnic diversity. Prevalence rates of off-licence prescribing were calculated as proportions within each hospital trust. Differences in prevalence based on clinical reason for off-licence use and ethnicity were explored descriptively.

Results

On 1st November 2025, a total of 3115 patients were prescribed clozapine across four NHS Trusts. Of these, 751 (24%) received clozapine under off-licence conditions. The highest proportion of off-licence prescribing was observed at SLaM (48%; n = 612) followed by ELFT (12%; n = 79), with lower rates at SWLSTG (5%; n = 36) and NHT (5%; n = 24). SLaM had the greatest proportion of patients receiving extended three-monthly haematological monitoring (40%; n = 517), a key driver of off-licence use, while this practice was rare or absent in other Trusts. Black patients were disproportionately represented among those prescribed clozapine off-licence for reasons other than extended monitoring, with BEN monitoring being the most frequent reason.

Conclusion

Off-licence prescribing of clozapine offers a pragmatic and timely alternative to optimise its therapeutic benefits for individuals with severe, treatment-resistant psychiatric disorders, while regulatory changes are awaited. The higher rate of of-licence use in SLaM likely reflects a concentration of specialist expertise rather than a model that is immediately generalisable.

Item Type: Article
DOI/Identification number: 10.1016/j.schres.2026.08.010
Additional information: For the purpose of open access, the author(s) has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.
Uncontrolled keywords: clozapine; off-licence; schizophrenia; monitoring
Subjects: R Medicine
Institutional Unit: Schools > Kent and Medway Medical School
Former Institutional Unit:
There are no former institutional units.
Funders: University of Kent (https://ror.org/00xkeyj56)
Depositing User: Ian Badger
Date Deposited: 12 Nov 2026 15:03 UTC
Last Modified: 13 Nov 2026 12:16 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/117735 (The current URI for this page, for reference purposes)

University of Kent Author Information

  • Depositors only (login required):

Total unique views of this page since July 2020. For more details click on the image.